Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06005493 · ClinicalTrials.gov registry record · Phase 1

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

A Phase 1 study of Gastric Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 1
Development phase
280
Enrollment target
20
Study locations

NCT06005493 is a Phase 1 study of Gastric Cancer and Pancreatic Ductal Adenocarcinoma that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 280 participants, below the 317-participant average among 153 other Gastric Cancer trials with a reported enrollment target (12% lower). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06005493, a Phase 1 study of Gastric Cancer and Pancreatic Ductal Adenocarcinoma, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 1
Development phase
280 participants
Enrollment target
20
Study locations

Study Summary

This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe, tolerable and has anti-cancer activity in patients with advanced solid tumors.

Conditions Studied

Gastric Cancer Pancreatic Ductal Adenocarcinoma Esophageal Adenocarcinoma Gastro-esophageal Junction Cancer

Interventions

  • DRUG AZD5863

Study Locations (20)

Other

  • Research Site - Beijing
  • Research Site - Beijing
  • Research Site - Shandong
  • Research Site - Toulouse
  • Research Site - Villejuif
  • Research Site - Chūōku
  • Research Site - Kashiwa
  • Research Site - Kōtoku
  • Research Site - Amsterdam
  • Research Site - Groningen
  • Research Site - Rotterdam
  • Research Site - Seoul
  • Research Site - Seoul
  • Research Site - Seoul
  • Research Site - Seoul
  • Research Site - Kaohsiung City
  • Research Site - Tainan

Florida

  • Research Site - Jacksonville

Minnesota

  • Research Site - Rochester

New York

  • Research Site - New York

Trial Details

FieldValue
Enrollment Target 280 participants
Start Date 2023-07-11
Est. Completion 2027-07-16
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06005493

The ClinicalTrials.gov registry entry for NCT06005493 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 280 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 317-participant average among 153 other Gastric Cancer trials with a reported enrollment target (12% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 1 intervention - of which AZD5863 is the first listed.

NCT06005493 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Other, Florida, Minnesota.

Frequently Asked Questions

What is clinical trial NCT06005493 about?

NCT06005493 is a clinical study titled "Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors". This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe, tolerable and has anti-cancer activity in patients with advanced solid tumors.

What is the current status of trial NCT06005493?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 280 participants. The study started on 2023-07-11. Estimated completion is 2027-07-16.

What conditions does trial NCT06005493 study?

This clinical trial studies the following conditions: Gastric Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma, Gastro-esophageal Junction Cancer.

What interventions are being tested in trial NCT06005493?

The interventions under investigation include: AZD5863 (DRUG).

Who is sponsoring clinical trial NCT06005493?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06005493 being conducted?

This trial has 20 study locations across Florida, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gastric Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Gastric Cancer

All registered trials for this condition

Pancreatic Ductal Adenocarcinoma

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.